-
UPC Court of Appeal upholds Abbott’s glucose sensor patent: rejects Sibio’s added matter, inventive step attacks
Read more: UPC Court of Appeal upholds Abbott’s glucose sensor patent: rejects Sibio’s added matter, inventive step attacksThe UPC Court of Appeal has dismissed Sibio’s bid to revoke Abbott’s continuous glucose monitor patent, confirming its own earlier finding from a related injunction case and issuing two headnotes that will guide how the court treats omitted features in future added matter disputes.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
Read more: China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂA Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.
-
UPC Roundup (1 week): EPO appeal leads to Munich LD stay; Munich LD flags novel damages issues; and more
Read more: UPC Roundup (1 week): EPO appeal leads to Munich LD stay; Munich LD flags novel damages issues; and moreThis is a summary of developments in and around the UPC in the calendar week of August 10, 2026.
-
Federal Circuit affirms invalidation of Nielsen’s audience-measurement patent, backs PTAB’s “reasonably pertinent” prior art finding
Read more: Federal Circuit affirms invalidation of Nielsen’s audience-measurement patent, backs PTAB’s “reasonably pertinent” prior art findingThe Federal Circuit affirmed a PTAB ruling invalidating Nielsen’s audience-measurement patent, holding that a facial-expression research paper qualified as “reasonably pertinent” prior art despite coming from a different research field.
-
EWHC hinders Accord’s plans to launch Entresto competing product in Novartis patent dispute
Read more: EWHC hinders Accord’s plans to launch Entresto competing product in Novartis patent disputeMr. Justice Meade of the High Court of Justice for England & Wales has held that all of Accord’s “attacks” on a Novartis Entresto patent have failed, and its own intended competing product would infringe the defendant’s supplementary protection certificate.
-
New Munich FRAND guidelines bless Avanci 5G terms: balanced analysis shows why Tesla may not save royalties through UK litigation
Read more: New Munich FRAND guidelines bless Avanci 5G terms: balanced analysis shows why Tesla may not save royalties through UK litigationThe Munich I Regional Court’s 7th Civil Chamber has just released a comprehensive and updated
-
UPC Munich LD flags novel questions on damages law in Edwards v. Meril damages claim, flags novel questions on applicable law and non-infringing substitute profits
Read more: UPC Munich LD flags novel questions on damages law in Edwards v. Meril damages claim, flags novel questions on applicable law and non-infringing substitute profitsAt an interim hearing, the Munich LD set Edwards’ damages claim against Meril at a €15 million value in dispute and previewed how it may rule on two open legal questions.
-
Patent Litigation Europe returns for 2027, building on last year’s rebrand into three co-located tracksÂ
Read more: Patent Litigation Europe returns for 2027, building on last year’s rebrand into three co-located tracksÂSpeakers already confirmed for the event include Hon. Emmanuel Gouge and Aleš Zalar of the UPC, Judge Oliver Schön of the Munich Regional Court, Abbott’s Gael Tisack, Ericsson’s Gabriele Mohsler, Nokia’s Clemens Heusch, and SIM IP’s Erich Spangenberg.
Follow Us
Latest Articles
- UPC Court of Appeal upholds Abbott’s glucose sensor patent: rejects Sibio’s added matter, inventive step attacks
- China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
- UPC Roundup (1 week): EPO appeal leads to Munich LD stay; Munich LD flags novel damages issues; and more
- Federal Circuit affirms invalidation of Nielsen’s audience-measurement patent, backs PTAB’s “reasonably pertinent” prior art finding
- EWHC hinders Accord’s plans to launch Entresto competing product in Novartis patent dispute